Top Markets
Coin of the day
Regulus Therapeutics Inc. Regulus Therapeutics Inc.

Regulus Therapeutics Inc.

RGLS
Rank in Stocks #17600
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Share Price
$8.16
Last synced: 2025-06-26
Market Cap
$234.57M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Regulus Therapeutics Inc. (RGLS)

Category

Stock split history for Regulus Therapeutics Inc. (RGLS)
Regulus Therapeutics Inc. stock (symbol: RGLS) underwent a total of 2 stock splits.
The most recent stock split occurred on Jun 29, 2022.
One RGLS share bought prior to Oct 04, 2018 would equal to 0.0083333333333333 RGLS shares today.
Stock split list
Year Split Multiple Cumulative Multiple
2022-06-29 1:10 x0.1 x0.0083333333333333
2018-10-04 1:12 x0.083333333333333 x0.083333333333333
Stock splits for similar companies or competitors
Company Number of stock splits Cumulative Multiple Country
1 x2
US
0 -
NL
0 -
US
1 x3
AU
0 -
CH